Reviewing Dr. Reddy’s Laboratories (NYSE:RDY) & LENZ Therapeutics (NASDAQ:LENZ)

Dr. Reddy’s Laboratories (NYSE:RDY) and LENZ Therapeutics (NASDAQ:LENZ) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Dr. Reddy’s Laboratories and LENZ Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy’s Laboratories	$329.84 billion	0.03	$308.83 million	$0.37	37.18
LENZ Therapeutics	$21.48 million	4.61	-$128.51 million	($4.09)	-0.77

Dr. Reddy’s Laboratories has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dr. Reddy’s Laboratories and LENZ Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dr. Reddy’s Laboratories	N/A	N/A	N/A
LENZ Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

3.8% of Dr. Reddy’s Laboratories shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy’s Laboratories shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Dr. Reddy’s Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Dr. Reddy’s Laboratories and LENZ Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy’s Laboratories	1	3	2	0	2.17
LENZ Therapeutics	1	2	4	0	2.43

Dr. Reddy’s Laboratories presently has a consensus price target of $492.90, indicating a potential upside of 3,483.42%. LENZ Therapeutics has a consensus price target of $23.00, indicating a potential upside of 630.16%. Given Dr. Reddy’s Laboratories’ higher possible upside, equities analysts clearly believe Dr. Reddy’s Laboratories is more favorable than LENZ Therapeutics.

Summary

LENZ Therapeutics beats Dr. Reddy’s Laboratories on 6 of the 11 factors compared between the two stocks.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.